Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: BarryH who wrote (2098)	10/4/1997 2:16:00 PM
From: sam	of 6136

Good question. But I would pose the question differently. How much is Agouron worth notwithstanding Viracept sales potential. Developing Viracept, getting it through the FDA, to market, and taking market share from the existing P.I.s, in direct competition with major pharmaceutical companies like Merck and Abbott Labs ADDS value to Agouron's share price. From what I can tell (please correct me if I am wrong), Agouron has AG-331 (phase 1, II), AG-3340, AG-2034, AG-3340, and AG-337 (Thymitaq) in various clinical stages. Its cancer program, "validated by Roche, remains largely unnoticed by the street" (according to Doug Lind). Dr. Lind goes on to say that "Agouron may ultimately be known equally as a cancer company." Now how are these products valued? Any input would be greatly appreciated.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next